GlassScriptPhysician profile
Elizabeth A Brown
NPI 1427018423
$2,675.79
in general payments reported to CMS, 2019-2025
21 companies · $542 in 2025
The $542 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $154 · 2021: $110 · 2022: $500 · 2023: $440 · 2024: $646 · 2025: $542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $612.13 | 2022-2025 | Lumigan, Alphagan P |
| Bausch & Lomb Americas INC. | $349.43 | 2022-2025 | Miebo, Vyzulta, Prolensa |
| Alcon Vision LLC | $296.07 | 2020-2025 | Rocklatan, Argos, Tryptyr |
| Allergan, INC. | $198.63 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $194.32 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $172.89 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $144.01 | 2022-2024 | Tyrvaya |
| Biotissue Holdings INC. | $107.94 | 2022-2023 | |
| Sight Sciences, INC. | $100.28 | 2022 | |
| Dompe US, INC. | $90.17 | 2025 | Oxervate |
| Aerie Pharmaceuticals, INC. | $85.37 | 2019-2021 | |
| Amgen INC. | $77.71 | 2024-2025 | Tepezza |
| Horizon Therapeutics Plc | $74.92 | 2022-2023 | Tepezza |
| Rayner Intraocular Lenses Limited | $53.78 | 2022-2025 | Omidria |
| Rxsight INC | $33.08 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Light Adjustable Lens (Lal) |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $18.75 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.79 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $12.86 | 2021 | |
| Sun Pharmaceutical Industries INC. | $12.84 | 2021 | |
| Lkc Technologies, INC. | $12.28 | 2025 | |
| New World Medical,INC. | $11.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.